Drug intelligence / Profile preview

tofogliflozin

Development stage: Phase 4
Lead developer: Kowa
Modality: Small Molecules
Administration: Oral

Overview

Tofogliflozin is a small molecule drug belonging to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. It was developed for the treatment of type 2 diabetes mellitus (T2DM). Tofogliflozin works by selectively inhibiting SGLT2 in the kidneys, thereby reducing glucose reabsorption and promoting urinary glucose excretion, which leads to lower blood glucose levels. The drug has demonstrated efficacy in reducing HbA1c, fasting plasma glucose, body weight, and blood pressure in patients with T2DM. It is generally well tolerated but may increase the risk of urinary tract and genital infections due to its mechanism of action[3][4][5][6].

Brand names: AplewayDebereza
Other names: tofogliflozin anhydrous

Targets

SGLT2 (Sodium-glucose cotransporter protein subunit 2)

Beyond the preview

Go deeper on tofogliflozin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tofogliflozin.

Explore the full profile